Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,780,877

« Back to Dashboard

Which drugs does patent 6,780,877 protect, and when does it expire?


Patent 6,780,877 protects BEPREVE and is included in one NDA. There has been one Paragraph IV challenge on Bepreve.

This patent has thirty-three patent family members in fifteen countries.

Summary for Patent: 6,780,877

Title: Acid addition salt of optically active piperidine compound and process for preparing the same
Abstract:The present invention is to provide a benzenesulfonic acid salt and a benzoic acid salt of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid represented by the formula (I): ##STR1## wherein * represents an asymmetric carbon, which are excellent in antihistaminic activity and anti-allergic activity, and a process for producing the same.
Inventor(s): Kita; Jun-ichiro (Ube, JP), Fujiwara; Hiroshi (Ube, JP), Takamura; Shinji (Ube, JP)
Assignee: Ube Industries, Ltd. (Ube, JP) Tanabe Seiyaku Co., Ltd. (Osaka, JP)
Application Number:09/949,809
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bausch And Lomb Inc
BEPREVE
bepotastine besilate
SOLUTION/DROPS;OPHTHALMIC022288-001Sep 8, 2009RXYesYes6,780,877► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,780,877

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-347851Dec 26, 1996
Japan8-347853Dec 26, 1996
Japan8-347895Dec 26, 1996

Non-Orange Book Patents for Patent: 6,780,877

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,307,052 Acid-addition salts of optically active piperidine compound and process for producing the same► Subscribe
7,282,589Acid addition salt of optically active piperidine compound and process for preparing the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,780,877

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan4562229► Subscribe
Japan5518928► Subscribe
Japan2014012732► Subscribe
Japan2012180360► Subscribe
Japan5360605► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot